#Germany #Berlin #Hengrui Pharma #oncology research #ESMO Congress

Hengrui Pharma Shines at ESMO 2025

From October 17 to 21, Berlin hosted the European Society for Medical Oncology (ESMO) Annual Congress, a gathering that united the forefront leaders in oncology and pharmaceutical innovation. Among the standout participants was Hengrui Pharma, a symbol of China's rapidly progressing biopharmaceutical sector, which made a remarkable entry as an exhibitor at this prestigious event.

Hengrui's presence at ESMO was particularly noteworthy, marking ten consecutive years of showcasing pioneering research in the field. This year, the company presented an impressive portfolio encompassing 46 studies across 14 innovative therapeutic programs. These included nine oral presentations, two mini oral sessions, and four late-breaking abstracts (LBAs), providing a comprehensive view of their research strength and commitment to tackling various forms of cancer.

Breaking New Ground

Not only did Hengrui highlight its ongoing research, but it also fostered discussions on the future of oncology at a dedicated roundtable titled "China Innovation Going Global." This session focused on strategic pathways for the global spread of innovations originating from China. During the global launch of the CARES-009 study, leading experts presented data from their innovative therapeutic combination which has drawn the attention of the international oncology community.

Ms. Jo Feng, Hengrui's President and COO, commented on the significance of the Congress: "ESMO 2025 has allowed us to illustrate our increasing academic involvement internationally. Our focus remains on medical innovation aimed at fulfilling unmet clinical needs as we continue to prioritize patient care on a global scale."

Expansive Research Portfolio

The breadth of Hengrui’s research at this year's Congress was extensive, covering various cancer types including but not limited to esophagogastric, gynecologic malignancies, liver cancer, breast cancer, pancreatic cancer, and more. In particular, the offerings in breast cancer research were profound, with eleven studies presented which included pivotal work on their antibody-drug conjugate (ADC) trastuzumab rezetecan. This specific study compared its effectiveness with pyrotinib plus capecitabine for HER2-positive cases, exemplifying Hengrui's enduring commitment to advancing breast cancer care.

A total of 14 studies on gastrointestinal cancers and six on lung cancer further underscored their robust capabilities across multiple domains. The lung cancer studies particularly showcased results with both non-small cell and small cell lung cancer—underscoring the versatility and clinical potential engendered by their therapeutic strategies.

The decision to pivot towards innovative solutions in areas like thymic epithelial tumors and additional malignancies showcases Hengrui's expansive ambitions and its readiness to explore and fill the gaps in current treatment regimens, particularly amidst evolving standards of care.

A Future-Focused Vision

Since its participation began in 2016, Hengrui has consistently pushed boundaries and raised standards for Chinese pharmaceutical companies, with more than 119 research achievements presented over these years. As the Congress continues to attract thousands from around the world, Hengrui's presence is increasingly influential, bringing Chinese innovation to a broader audience and redefining the landscape of cancer care.

Looking towards the future, Hengrui Pharma is dedicated to continuing its robust research agenda, leveraging its global R&D network to ensure that new treatment modalities reach patients worldwide. This commitment not only aims to enhance clinical outcomes but also embodies Hengrui's overarching vision of patient-centric care driven by scientific excellence.

Through its resolute efforts in expanding its therapeutic pipeline and engaging in global academic discourse, Hengrui Pharma is not just participating in the oncology conversation; it is actively shaping it, ensuring a promising future for cancer treatment options across the globe.

Conclusion

As the ESMO Congress concluded, Hengrui’s activities this year solidified their status as pioneers not only within China but also on the international stage, reaffirming their role in the future of oncological treatments through groundbreaking research and innovations. Their journey exemplifies the transformation and ambition of a company steadfastly focused on enhancing patient care and bridging global healthcare needs.